Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 8, 2024Cardiology in ReviewOpen Access

SGLT2 inhibitors benefit heart failure across the LVEF spectrum via mechanisms beyond glycosuria and natriuresis.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Despite proven cardioprotective benefits across the spectrum of left ventricular dysfunction, the mechanisms by which sodium-glucose cotransport 2 inhibitors exert these effects remain poorly understood.

Design

Review

Key result

SGLT2 inhibitors provide cardioprotective benefits in heart failure across the spectrum of left ventricular dysfunction through mechanisms extending beyond glycosuria and natriuresis.

Authors

PSPatrick SavageLDLana DixonDGDavid Grieve

Discussion

Loading...

Member takes

Overview

Supports SGLT2 inhibitor use across the heart failure spectrum; leaves open the dominant nonglycosuric mechanisms.

Structured PICO

P
Population
Patients with heart failure across the spectrum of left ventricular dysfunction
I
Intervention
Sodium-glucose cotransport 2 (SGLT2) inhibitors (including dapagliflozin and empagliflozin)

This review summarizes the cardioprotective benefits of SGLT2 inhibitors in heart failure and explores potential mechanisms of action beyond their diuretic and glycemic effects.

Cite This Study

Savage et al. (2024) conducted a review in Heart failure. SGLT2 inhibitors was evaluated. SGLT2 inhibitors provide cardioprotective benefits in heart failure across the spectrum of left ventricular dysfunction through mechanisms extending beyond glycosuria and natriuresis.

synapsesocial.com/papers/6a092f034c1e2db30bd2618ehttps://doi.org/10.1097/crd.0000000000000637
View Full Paper
Ask AI
Bookmark
Share